For the quarter ending 2025-09-30, JANX had -$4,057K decrease in cash & cash equivalents over the period. -$12,949K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -24,313 | -57,366 |
| Depreciation | 501 | 1,060 |
| Stock-based compensation | 9,044 | 21,662 |
| Accretion of discounts on investments, net | 4,623 | 9,427 |
| Prepaid expenses and other current assets | -449 | 1,049 |
| Accounts receivable | - | 0 |
| Other long-term assets | -66 | -191 |
| Accounts payable | -168 | -524 |
| Accrued expenses | 6,179 | 4,627 |
| Deferred revenue | 0 | 0 |
| Operating lease right-of-use assets and liabilities, net | -9 | 11 |
| Net cash used in operating activities | -12,856 | -40,837 |
| Purchases of property and equipment | 93 | 844 |
| Purchases of short-term investments | 117,969 | 463,976 |
| Maturities of short-term investments | 126,368 | 125,990 |
| Net cash used in investing activities | 8,306 | -338,830 |
| Proceeds from exercise of common stock options and employee stock purchase plan | 493 | 1,855 |
| Proceeds from the issuance of common stock and pre-funded common stock warrants, net of issuance costs | 0 | -347 |
| Net cash provided by financing activities | 493 | 1,508 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -4,057 | -378,159 |
| Cash and cash equivalents at beginning of period | 431,421 | - |
| Cash and cash equivalents at end of period | 49,205 | - |
Janux Therapeutics, Inc. (JANX)
Janux Therapeutics, Inc. (JANX)